<DOC>
	<DOCNO>NCT02686372</DOCNO>
	<brief_summary>Hepatocellular Carcinoma ( HCC ) recurrence rate high among liver transplant patient , treatment measure limit . This study plan recruit 10 subject Hepatitis B virus ( HBV ) relate HCC liver transplantation . The objective study ass safety , tolerability effectiveness HBV specific T cell receptor ( HBV/TCR ) redirect T cell target population .</brief_summary>
	<brief_title>TCR-Redirected T Cell Infusions Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation</brief_title>
	<detailed_description>A single arm open label trial patient hepatocellular carcinoma HBV infection ( HBsAg+ ) post liver transplantation . For patient successfully match TCR histocompatibility locus antigen ( HLA ) restriction , escalate dos HBV/TCR express autologous T cell infuse . Tests do confirm safety efficacy two-month treatment observation period twice year follow period five year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>Diagnosis hepatocellular carcinoma ( HCC ) Underwent liver transplantation Seropositive hepatitis B surface antigen liver transplantation No major postoperative complication Life expectancy least 12 week Ability provide inform consent Ability comply study procedures Patients reproductive potential must agree use approve contraceptive method , test negative serum urine pregnancy test result within 14 day prior enrolment . Administration cell therapy , include NK , CIK , DC , CTL , CART , stem cell combine therapy kind within 3 month prior enrolment Second primary malignancy clinically detectable time consideration study enrolment Likelihood require steroid treatment period clinical trial HLA profile match HLAclass I restriction element available T cell receptor Any concurrent liver infection hepatitis A , C D infection Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection Known Central Nervous System tumours include metastatic brain disease . Any condition unstable could jeopardise safety patient his/her compliance study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
</DOC>